Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30747687 | 1.00 | TLR7 (1.00) | TLR7IL6 | |
| SCHEMBL27249641 | 1.00 | TLR7 (1.00) | TLR7IL6 | |
| SCHEMBL27249640 | 1.00 | TLR7 (1.00) | TLR7IL6 | |
| SCHEMBL30747804 | 0.92 | TLR7 (0.85) | TLR7IL6 | |
| SCHEMBL27249516 | 0.92 | TLR7 (0.85) | TLR7IL6 | |
| SCHEMBL1146385 | 0.85 | TLR7 (0.74) | TLR7IL6 | |
| SCHEMBL30323751 | 0.85 | TLR7 (0.74) | TLR7IL6 | |
| SCHEMBL30747776 | 0.85 | TLR7 (0.88) | TLR7 | |
| SCHEMBL30747810 | 0.85 | TLR7 (0.88) | TLR7 | |
| SCHEMBL27249637 | 0.85 | TLR7 (0.88) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554678-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-21 | — | — | EP | claimed |
| WO-2024013205-A9 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-10 | — | — | WO | claimed |
| WO-2024013205-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-18 | — | — | WO | claimed |
| US-20250215032-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4554678-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024013205-A9 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024013205-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215032-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | CDK1, UPP1, CDK10 | TLR7 4573/4885IL6 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.